In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae.
The in vitro susceptibilities of 12 strains of Chlamydia pneumonia to a new quinolone, OPC-17116; ofloxacin; and sparfloxacin were determined. OPC-17116 was slightly less active than sparfloxacin but more active than ofloxacin, with a MIC for 90% of strains tested and a minimal chlamydiacidal concentration for 90% of strains tested of 0.5 micrograms/ml.
Roblin
P M
PM
Department of Pediatrics, State University of New York Health Science Center at Brooklyn 11203.
Montalban
G
G
Hammerschlag
M R
MR
D000890:Anti-Infective Agents / Q000494:pharmacology*; D016993:Chlamydophila pneumoniae / Q000187:drug effects*; D024841:Fluoroquinolones; D008826:Microbial Sensitivity Tests; D015242:Ofloxacin / Q000494:pharmacology*; D010879:Piperazines / Q000494:pharmacology*; D015363:Quinolones / Q000494:pharmacology*
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D010879:Piperazines; D015363:Quinolones; D015242:Ofloxacin; C075375:grepafloxacin; C061363:sparfloxacin